Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Liarozole

H M Bryson1, A J Wagstaff

  • 1Adis International Limited, Auckland, New Zealand.

Drugs & Aging
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Liarozole inhibits enzymes to spare retinoic acid and reduce prostate cancer tumor size. Clinical trials show partial responses in patients with relapsed prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis.

QJM : monthly journal of the Association of Physicians·2014
Same author

No lasting legacy: no change in reporting of women's sports in the British print media with the London 2012 Olympics and Paralympics.

Journal of public health (Oxford, England)·2014
Same author

Tetravalent human-rhesus reassortant rotavirus vaccine: a review of its immunogenicity, tolerability and protective efficacy against paediatric rotavirus gastroenteritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Recombinant interferon-beta-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Recombinant Mammalian Cell-Derived Somatropin: A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Wasting Associated with HIV Infection.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Pharmacology
  • Oncology
  • Endocrinology

Background:

  • Liarozole inhibits 4-hydroxylase, preventing retinoic acid catabolism and exerting retinoid-sparing effects.
  • Liarozole also inhibits aromatase and 17, 20-lyase, impacting estrogen and androgen synthesis.
  • While acute liarozole administration lowers testosterone, chronic administration leads to normalization via pituitary feedback.

Purpose of the Study:

  • To evaluate the anti-cancer effects of liarozole in prostate cancer models.
  • To assess the efficacy of liarozole in patients with relapsed prostate cancer.

Main Methods:

  • Inhibition of key enzymes involved in retinoic acid and steroid hormone metabolism.
  • Administration of liarozole in animal models of prostate carcinoma.

Related Experiment Videos

  • Phase I and II clinical trials in patients with relapsed prostate cancer.

    • Main Results:

    • Liarozole reduced tumor size in androgen-dependent and -independent prostate carcinoma models.
    • Liarozole demonstrated chemopreventive activity in vivo.
    • In clinical trials, liarozole achieved complete response in 4% and partial response in 26% of prostate cancer patients.

    Conclusions:

    • Liarozole exhibits anti-tumor and chemopreventive properties against prostate cancer.
    • Liarozole shows clinical activity in patients with relapsed prostate cancer, warranting further investigation.
    • Cutaneous adverse events were the most common side effects, resembling those of excess retinoic acid.